Tar­get­ing Bio­Mar­in's new drug fran­chise, Bridge­Bio CEO Neil Ku­mar cel­e­brates an in­ter­im win. But is it good enough?

Over the past few months, Bridge­Bio CEO Neil Ku­mar has been cut­ting deep to re­pair the dam­age of a crush­ing Phase III fail at the end of last year: re­duc­ing staff, do­ing deals and lin­ing up cash to pay for op­er­a­tions to get through a se­ries of key da­ta read­outs. To­day, we’re get­ting one of those clas­sic in­flec­tion points — an in­ter­im Phase II read­out of in­fi­gra­tinib for dwarfism — and it’s com­ing up pos­i­tive in one co­hort.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER